Scholarlink

Purpose <p>To evaluate the usefulness of the systemic immune-inflammation index (SII) and systemic inflammation response index (SIRI) in predicting local tumor control (LC) duration and overall survival (OS) in patients with brain metastases treated with primary stereotactic radiosurgery (SRS).</p> Methods <p>All consecutive patients who underwent fractionated SRS between April 2018 and December 2022 were retrospectively analyzed. Statistical analyses included Cox regression and Kaplan-Meier curves.</p> Results <p>A total of 132 metastases in 65 patients were analyzed. The median SII was 909 (IQR 524–1696), and the median SIRI was 1.6 (IQR 0.7–3.1). The median LC duration was 10 months, with 66.7% of lesions under control, 13.6% progressed, and 19.7% had unknown status due to insufficient imaging. The median OS was 11 months; 83% of patients had died by the last follow-up. SII and SIRI were not associated with LC duration in univariable Cox regression analysis. However, higher SII (<i>p</i> = 0.05) was significantly associated with worse OS in multivariable Cox regression analysis, along with male sex (<i>p</i> &lt; 0.01) and gastrointestinal cancer origin (<i>p</i> = 0.02). These findings were also supported by Kaplan-Meier curves with log-rank tests. The optimal SII cutoff for predicting OS was 2600 (concordance index 0.72; hazard ratio 2.65). SIRI was associated with OS in univariate analysis (<i>p</i> = 0.03), but not multivariable analysis.</p> Conclusion <p>This study suggests that higher SII was associated with worse OS and that it can be useful markers to predict OS, but not LC duration.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Systemic immune-inflammation index as a prognostic biomarker to predict overall survival after primary stereotactic radiosurgery for brain metastases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月15日

查看全文
  • Sukwoo Hong,
  • Hirokazu Takami,
  • Motoyuki Umekawa,
  • Yuki Shinya,
  • Hirotaka Hasegawa,
  • Mariko Kawashima,
  • Yosuke Kitagawa,
  • Masashi Nomura,
  • Shunsaku Takayanagi,
  • Shota Tanaka,
  • Nobuhito Saito

摘要

Purpose

To evaluate the usefulness of the systemic immune-inflammation index (SII) and systemic inflammation response index (SIRI) in predicting local tumor control (LC) duration and overall survival (OS) in patients with brain metastases treated with primary stereotactic radiosurgery (SRS).

Methods

All consecutive patients who underwent fractionated SRS between April 2018 and December 2022 were retrospectively analyzed. Statistical analyses included Cox regression and Kaplan-Meier curves.

Results

A total of 132 metastases in 65 patients were analyzed. The median SII was 909 (IQR 524–1696), and the median SIRI was 1.6 (IQR 0.7–3.1). The median LC duration was 10 months, with 66.7% of lesions under control, 13.6% progressed, and 19.7% had unknown status due to insufficient imaging. The median OS was 11 months; 83% of patients had died by the last follow-up. SII and SIRI were not associated with LC duration in univariable Cox regression analysis. However, higher SII (p = 0.05) was significantly associated with worse OS in multivariable Cox regression analysis, along with male sex (p < 0.01) and gastrointestinal cancer origin (p = 0.02). These findings were also supported by Kaplan-Meier curves with log-rank tests. The optimal SII cutoff for predicting OS was 2600 (concordance index 0.72; hazard ratio 2.65). SIRI was associated with OS in univariate analysis (p = 0.03), but not multivariable analysis.

Conclusion

This study suggests that higher SII was associated with worse OS and that it can be useful markers to predict OS, but not LC duration.